$RHHBY Roche Holdings Ltd A (RHHBY)
42.95 ? -1.08 (-2.45%)
Volume: 1,345,422 @07/24/20 4:42:45 PM EDT
Bid Ask Day's Range
42.95 43.12 42.71 - 43.29
RHHBY Detailed Quote
42.95 ? -1.08 (-2.45%)
Volume: 1,345,422 @07/24/20 4:42:45 PM EDT
Bid Ask Day's Range
42.95 43.12 42.71 - 43.29
RHHBY Detailed Quote
Recent RHHBY News
- Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY) • IH Market News • 05/19/2026 02:48:10 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • InvestorsHub NewsWire • 04/22/2026 01:00:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- /C O R R E C T I O N -- Roche/ • PR Newswire (US) • 03/24/2026 08:05:00 PM
- /C O R R E C T I O N -- Roche/ • PR Newswire (US) • 03/24/2026 07:27:00 PM
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets • PR Newswire (US) • 03/24/2026 06:00:00 AM
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets • PR Newswire (US) • 03/24/2026 06:00:00 AM
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation • PR Newswire (US) • 03/18/2026 01:00:00 PM
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease • PR Newswire (US) • 03/16/2026 06:00:00 AM
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease • PR Newswire (US) • 03/16/2026 06:00:00 AM
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools • PR Newswire (US) • 03/05/2026 06:15:00 AM
- Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development • InvestorsHub NewsWire • 02/19/2026 02:00:00 PM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/28/2026 07:33:05 PM
- Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation • AllPennyStocks.com • 01/05/2026 05:38:00 PM
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology • AllPennyStocks.com • 12/22/2025 11:45:00 AM
- AstraZeneca Reports Fasenra Misses Primary Endpoint in COPD Study • UK Market News • 09/17/2025 08:28:22 AM
- Stopping Cancer Before It Spreads: The EMT Revolution in Oncology • AllPennyStocks.com • 09/08/2025 12:00:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • InvestorsHub NewsWire • 07/07/2025 01:00:00 PM
